ArticleDigestive diseases and sciences2002
p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis.
Article in Digestive diseases and sciences, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The prognostic significance of p53 expression in gastric cancer: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis.PloS one · 2014Pooled it
- C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.Molecular pathology : MP · 2003Trial
- Review
- Article
- Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer.Middle East journal of digestive diseases · 2022Review
- Impact ofMicroorganisms · 2020Article
- Tyrosine Kinases inToxins · 2019Review
- Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Journal of gastric cancer · 2016Article
- Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.OncoTargets and therapy · 2016Article
- MET in gastric cancer--discarding a 10% cutoff rule.Histopathology · 2016Observational
- Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.Oncotarget · 2015Review
- Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.Molecular medicine reports · 2015Article
- Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Biomedicines · 2015Review
- Article
- Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2014Article
- HER2 therapies and gastric cancer: a step forward.World journal of gastroenterology · 2013Review
- MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Molecular cancer therapeutics · 2012Article
- Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.Surgery today · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular mechanisms of Helicobacter pylori associated tumor development are poorly understood. The spectra of genetic alterations in neoplasms may provide clues to the molecular carcinogenesis of a tumor and may be relevant for the prognosis of the patients. We investigated the p53 mutation pattern and the protein expression of p53, c-erbB2, and c-met in 42 gastric cancers and correlated these alterations with H. pylori infection, histological subtypes and survival of the patients after curative resection. There were no differences in the incidences of the expression of p53, c-erbB2, and c-met in the tumor tissues according to H. pylori infection. Fifteen p53 mutations in 12 (29%) tumors were identified. More p53 mutations were found in patients with positive serology for H. pylori (43% vs 14%). This difference was not significant, but the small sample size may be insufficient to detect a potential statistical difference. There was neither a H. pylori-associated p53 hot-spot codon mutation nor a H. pylori characteristic mutational pattern of p53. Positive lymph nodes (P = 0.0061) and p53 mutations (P = 0.0035) were the only significant bad prognostic markers for survival after curative resection of the gastric cancers in our study. Our study does not indicate a unique molecular mechanism of p53 mutagenesis through H. pylori infection. The fact that p53 mutations were significantly correlated with poor survival of patients after potentially curative resection of gastric cancer may have clinical implications for multimodal therapies.
Indexed as
Identifiers
11837710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.